Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Brisson

Showing results (141-150 of 145) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 145 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2022
Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, CanadaDanuta M Skowronski, Yossi Febriani, Manale Ouakki, et al.
The Lancet. Infectious Diseases|March 7, 2015
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysisMélanie Drolet, Élodie Bénard, Marie-Claude Boily, et al.
The Lancet. Public Health|December 19, 2017
Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic modelsMarc Brisson, Élodie Bénard, Mélanie Drolet, et al.
Journal of Medicinal Chemistry|September 29, 2006
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infectionSrikanth Venkatraman, Stéphane L Bogen, Ashok Arasappan, et al.
Lancet (London, England)|January 31, 2021
Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling studyXiang Li, Christinah Mukandavire, Zulma M Cucunubá, et al.
Pageof 15

Showing results (141-150 of 145) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 145 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2022
Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, CanadaDanuta M Skowronski, Yossi Febriani, Manale Ouakki, et al.
The Lancet. Infectious Diseases|March 7, 2015
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysisMélanie Drolet, Élodie Bénard, Marie-Claude Boily, et al.
The Lancet. Public Health|December 19, 2017
Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic modelsMarc Brisson, Élodie Bénard, Mélanie Drolet, et al.
Journal of Medicinal Chemistry|September 29, 2006
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infectionSrikanth Venkatraman, Stéphane L Bogen, Ashok Arasappan, et al.
Lancet (London, England)|January 31, 2021
Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling studyXiang Li, Christinah Mukandavire, Zulma M Cucunubá, et al.
Pageof 15